Most Read Articles
Saras Ramiya, 20 Feb 2018
US researchers show split liver transplantation and living donor liver transplantation (LDLT) may be superior to whole liver transplantation in improving outcomes in paediatric patients.
Pank Jit Sin, 27 Apr 2018
A multispecialty team of healthcare professionals in University of Malaya (UM) has successfully carried out their first living donor liver transplantation last year and since then performed three living donor liver transplants over the past year. 
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

Pank Jit Sin, 28 Jun 2017
Liver Update is a series of international scientific meetings organized by the Malaysian Liver Foundation. It is meant to keep our healthcare professionals (HCPs) updated on current developments and new advances in the management of liver diseases. Usually held around mid to late July, the conference is a must-go for hepatologists, GPs and allied health professionals alike. 

Tenofovir alafenamide as good as tenofovir disoproxil fumarate for chronic HBV

27 Jan 2018
Hepatitis B is still widely prevalent worldwide despite effective vaccination programmes in many countries.

In patients with chronic hepatitis B virus (HBV) infection, tenofovir alafenamide (TAF) shows comparable 96-week efficacy and improved renal and bone safety with tenofovir disoproxil fumarate (TDF), a recent study has shown.

Researchers followed-up two international trial cohorts of chronic HBV patients who were randomized 2:1 to receive 25 mg of TAF or 300 mg of TDF. Outcomes included treatment efficacy in each trial and safety in the pooled population.

At 96 weeks post-treatment, both medications resulted in statistically comparable rates of viral suppression in patients positive for the hepatitis B surface antigen, with respective rates of 73 and 75 percent for TAF and TDF (adjusted difference, ‒2.2 percent; 95 percent CI, –8.3 to 3.9 percent; p=0.47).

The same trend was observed in patients negative for the antigen (90 percent vs 91 percent, respectively; adjusted difference, –0.6 percent; –7.0 to 5.8 percent; p=0.84).

In the pooled population for the safety analysis, TAF and TDF were administered to 866 and 432 patients, respectively. Majority of the adverse events reported were mild to moderate in severity, and only a small percentage of participants discontinued due to side effects (2 vs 1 percent, respectively).

Notably, those receiving TAF experienced significantly lower declines in hip bone mineral density (BMD) from baseline to 96 weeks (mean percentage decrease, –0.33 percent; –0.51 to –0.15) relative to those receiving TDF (–2.51 percent; –2.82 to –2.21; p<0.001). The trend was similar for spine BMD.

Finally, median increases in the estimated glomerular filtration rate were likewise significantly lower in TAF than in TDF (–1.2 vs –4.8 mL/min; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Saras Ramiya, 20 Feb 2018
US researchers show split liver transplantation and living donor liver transplantation (LDLT) may be superior to whole liver transplantation in improving outcomes in paediatric patients.
Pank Jit Sin, 27 Apr 2018
A multispecialty team of healthcare professionals in University of Malaya (UM) has successfully carried out their first living donor liver transplantation last year and since then performed three living donor liver transplants over the past year. 
Christina Lau, 22 Feb 2018

Cabozantinib, an oral inhibitor of multiple tyrosine kinases, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced hepatocellular carcinoma (HCC) whose disease progressed following sorafenib or other systemic therapies.

Pank Jit Sin, 28 Jun 2017
Liver Update is a series of international scientific meetings organized by the Malaysian Liver Foundation. It is meant to keep our healthcare professionals (HCPs) updated on current developments and new advances in the management of liver diseases. Usually held around mid to late July, the conference is a must-go for hepatologists, GPs and allied health professionals alike.